SEC Tracker
Get the app
CUE · XBRL financial data

Cue Biopharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CUE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers2,1001,821*1,7172,6583,3361,576*4212,9542,149year only5,6867,877
Research and development9,87410,887*10,1999,5309,3817,184*8,5477,9104,75416,532*6,89749,007
General and administrative3,6454,609*4,1863,5112,8674,021*4,1733,6794,9393,452*4,15246,565
Total operating expenses13,51915,653*14,38513,04112,15111,209*12,72011,5899,74419,964*11,03995,572
Operating income (loss)(11,419)(13,832)*(12,668)(10,383)(8,815)(9,633)*(12,299)(8,635)(7,595)1,978*(5,353)(87,695)
Interest expense254(718)*33——year only10033—year only——
Income tax expense (benefit)—————year only———year only——
Net income (loss)(11,005)(13,434)*(12,347)(10,171)(8,660)(9,496)*(12,257)(8,482)(7,448)1,585*(5,178)(153,067)
Earnings per share, basic USD per share(0.24)(0.28)*(0.25)(0.20)(0.17)—(0.17)(0.09)(0.07)0.01*(1.08)(24.14)
Earnings per share, diluted USD per share(0.24)(0.28)*(0.25)(0.20)(0.17)—(0.17)(0.09)(0.07)0.01*(1.08)(24.14)
Weighted average shares, basic thousands of shares46,35947,175*49,46750,17551,230—74,25595,459100,869107,906*4,8076,341
Weighted average shares, diluted thousands of shares46,35947,175*49,46750,17551,230—74,25595,459100,869107,906*4,8076,341
  • † Share count changed about 1/24 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (CUE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Cash and cash equivalents54,69148,51441,02930,02932,42022,45913,13627,49211,70127,13616,37917,392
Marketable securities00———0——6,971———
Accounts receivable1,6611,6981,4001,8473,15294505323875,5465,3515,377
Prepaid and other current assets1,1651,2422,2402,0241,6848051,8832,3503,1141,3091,7011,933
Total current assets57,51751,45444,66933,90037,25625,13815,93130,84425,81936,98326,39226,623
Property and equipment, net1,064795754667570471523454307241288255
Right-of-use asset7,0606,3235,5734,8104,0344,3703,5895,1184,6024,0743,3182,959
Total assets68,88861,53053,95142,32944,81032,19122,25440,70731,64442,21230,87730,707
Accounts payable2,4803,5013,9193,9066,4742,8233,7843,6272,3483,9483,3273,747
Accrued liabilities5,1274,1375,2084,5623,1992,9084,2301,5181,8711,6111,49914,883
Current portion of long-term debt4,0004,0004,0004,0004,000———————
Total current liabilities17,20717,08118,09016,45916,79013,68915,49819,25415,52413,4947,39121,218
Long-term debt5,1604,2023,2442,2861,3280——————
Lease liability, non-current3,8553,1622,5791,9621,3261,0031763,1042,6842,2861,8781,449
Total liabilities26,22224,44523,91320,70719,44414,69215,67422,54818,39815,7809,26928,397
Accumulated deficit(287,755)(301,190)(313,537)(323,708)(332,368)(341,864)(354,121)(362,603)(370,051)(368,466)(373,644)(526,711)
Total stockholders' equity42,66637,08530,03821,62225,36617,4996,58018,15913,24626,43221,6082,310
Total liabilities and equity68,88861,53053,95142,32944,81032,19122,25440,70731,64442,21230,87730,707
Common shares outstanding (cover page) thousands of shares45,12348,64348,64348,64363,35061,81975,35076,84678,73897,6614,0467,264
  • † Share count changed about 1/24 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (CUE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Net income (loss)(11,005)(13,434)*(12,347)(10,171)(8,660)(9,496)*(12,257)(8,482)(7,448)1,585*(5,178)(153,067)
Stock-based compensation2,073*2,072*1,9461,755*1,583*1,562*1,3381,263*1,533*610*4823,838*
Net cash from operating activities(7,799)*(10,958)*(9,784)(9,990)*(7,527)*(9,028)*(8,172)(3,415)*(9,024)*(1,076)*(10,942)(29,004)*
Purchases of property and equipment0*0*5510*(1)*2*15027*0*0*1210*
Net cash from investing activities5,000*0*(55)(10)*98*(1)*(150)(27)*(6,768)*7,020*(121)0*
Proceeds from issuing common stock—year only——10,821*(8)*——0*10,243*——
Share repurchases0*0*——————————
Net cash from financing activities4,589*4,782*2,354(1,000)*9,821*(932)*(1,000)17,798*1*9,492*30630,017*
Net change in cash1,790*(6,176)*(7,485)(11,000)*2,392*(9,961)*(9,322)14,356*(15,791)*15,436*(10,757)1,013*
  • † Share count changed about 1/24 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cue Biopharma17,3927,877(29,004)*7.3M0.6 quarters 10-QJun 30, 2026
Fitlife Brands1,089not reported3,635*9.4M— 10-QJun 30, 2026
Immucell8,8607,1863,019*9.1M— 10-QJun 30, 2026
Avalo Therapeutics85,382not reported(19,988)*53.6M20.0 quarters 10-QJun 30, 2026
Precision Biosciences81,6980(15,132)*27.9M6.1 quarters 10-QSep 30, 2026
iBio56,3950*(6,228)*64.3M14.1 quarters 10-KJun 30, 2026
Cyanotech6496,976108*7.4M— 10-QSep 30, 2025
Opus Genetics88,812755(11,950)*83.2M7.4 quarters 10-QJun 30, 2026
Acumen Pharmaceuticals53,075not reported(26,653)*72.3M3.4 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.